Navigation Links
Endocare Comments on Unsolicited Proposal
Date:8/7/2008

IRVINE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- The Board of Directors of Endocare, Inc. (Nasdaq: ENDO) received on August 6, 2008 an unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN) to purchase all of the outstanding shares of Endocare common stock for $2.28 per share in cash.

Endocare's Board of Directors, consistent with its fiduciary duties, and in consultation with its financial and legal advisors, will review and consider HealthTronics' unsolicited proposal carefully and promptly in the context of Endocare's strategic plans and pursue the best course of action for the long-term value to stockholders.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Investor Contact: Media Contact: For Additional Information:

Matt Clawson Len Hall Craig T. Davenport, CEO

Allen & Caron, Inc. Allen & Caron, Inc. Michael R. Rodriguez, CFO

(949) 474-4300 (949) 474-4300 Endocare, Inc.

matt@allencaron.com len@allencaron.com (949) 450-5400

http://www.allencaron.com http://www.allencaron.com http://www.endocare.com


'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Endocare Stock to Commence Trading on NASDAQ
2. Endocare Reports 2007 Third Quarter and Nine-Month Results
3. Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
4. Endocare Reports 2007 Annual and Fourth Quarter Financial Results
5. Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
6. Endocare Reports Financial Results for Second Quarter 2008
7. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
8. QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million
9. The Branded Pharmaceutical Association Comments on Hydrocodone
10. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
11. Pelosi Statement on Stark Comments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... mark for blood and service orders. Blood suppliers and their hospitals use ... , “BloodHub serves 13,000 active users across 2,100 hospitals who use our platform ...
(Date:5/4/2016)... , ... May 05, 2016 , ... “Less than 15% ... Little City Executive Director. “As one of ten non-profit organizations to participate and complete ... of Light. The ultimate benefit is that for every $1 we invest in volunteer ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... in grants to identify, fund and implement ideas aimed at improving care and ... , “Part of our vision for Trinity Health is to drive innovation ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare Systems ... announced it has secured $9 million in Series A funding led by TransLink ... will be used by Somnoware to further fulfill its mission to connect, organize ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... be familiar with watching a film or TV show in high definition, you may not ... Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s top brands as ... ... ... ...
Breaking Medicine Technology: